natgillin/translations-raw huggingface dataset:
Following intravenous administration, the volume of distribution of lomitapide was high (mean=1200 litres) despite a high degree ( &gt; 99.8%) of binding to plasma protein.
Nakon intravenske primjene, volumen distribucije lomitapida bio je visok (srednja vrijednost = 1200 litara) unatoč visokom stupnju ( &gt; 99,8%) vezanja na proteine plazme.
Following oral administration, fluticasone furoate was eliminated in humans mainly by metabolism with metabolites being excreted almost exclusively in faeces, with &lt; 1% of the recovered radioactive dose eliminated in the urine.
Nakon peroralne primjene, flutikazonfuroat se u ljudi uglavnom eliminirao metabolizmom, a metaboliti su se izlučivali gotovo isključivo u feces, pri čemu se &lt; 1% pronađene radioaktivne doze izlučilo u mokraću.
Following reintroduction of pazopanib, if transaminase elevations &gt; 3 x ULN recur, then pazopanib should be permanently discontinued.
Ako nakon ponovnog uvođenja pazopaniba ponovno dođe do porasta transaminaza na &gt; 3 x GGN, treba trajno prekinuti liječenje pazopanibom.
Following repeated subcutaneous administration to pregnant mice in the therapeutic dose range ( &gt; 0.5 mg/kg), asfotase alfa levels were quantifiable in fetuses at all doses tested, suggesting cross-placental transport of asfotase alfa.
Nakon ponavljane supkutane primjene skotnim ženkama miša u terapijskom rasponu doza ( &gt; 0,5 mg/kg), razine asfotaze alfa bilo je moguće kvantificirati u fetusima za sve testirane doze, što upućuje na prijenos asfotaze alfa kroz posteljicu.
Following single dose intravenous infusion of Aloxi 20 µg/kg, peak plasma concentrations (CT) reported at the end of the 15 minute infusion were highly variable in all age groups and tended to be lower in patients &lt; 6 years than in older paediatric patients.
Nakon jednokratne intravenske infuzije Aloxija u dozi od 20 µg/kg, vršne koncentracije u plazmi (CT) zabilježene na kraju 15-minutne infuzije bile su visoko varijabilne u svim dobnim skupinama i u bolesnika u dobi &lt; 6 godina kretale su se u nižim vrijednostima nego u starijih pedijatrijskih bolesnika.
Following single dose intravenous infusion of Aloxi 20 µg/kg, peak plasma concentrations (CT) reported at the end of the 15 minute infusion were highly variable in all age groups and tended to be lower in patients &lt; 6 years than in older paediatric patients.
Nakon jednokratne intravenske infuzije Aloxija u dozi od 20 µg/kg, vršne koncentracije u plazmi (CT) zabilježene na kraju 15-minutne infuzije, bile su visoko varijabilne u svim dobnim skupinama i u bolesnika u dobi &lt; 6 godina kretale su se u nižim vrijednostima nego u starijih pedijatrijskih bolesnika.
Following single dose intravenous infusion of palonosetron 20 mcg/kg, peak plasma concentrations (CT) reported at the end of the 15 minute infusion were highly variable in all age groups and tended to be lower in patients &lt; 6 years than in older paediatric patients.
Nakon jednokratne intravenske infuzije palonozetrona u dozi od 20 µg/kg, vršne koncentracije u plazmi (CT) zabilježene na kraju 15-minutne infuzije bile su visoko varijabilne u svim dobnim skupinama i u bolesnika u dobi &lt; 6 godina kretale su se u nižim vrijednostima nego u starijih pedijatrijskih bolesnika.
Following single dose intravenous infusion of Palonosetron 20 μg/kg, peak plasma concentrations (CT) reported at the end of the 15 minute infusion were highly variable in all age groups and tended to be lower in patients &lt; 6 years than in older paediatric patients.
Nakon jednokratne intravenske infuzije palonosetrona u dozi od 20 µg/kg, vršne koncentracije u plazmi (CT) zabilježene na kraju 15-minutne infuzije bile su visoko varijabilne u svim dobnim skupinama i u bolesnika u dobi &lt; 6 godina kretale su se u nižim vrijednostima nego u starijih pedijatrijskih bolesnika.
Following single oral administration of 14C-labeled Sivextro under fasted conditions, the majority of elimination occurred via the liver with 81.5% of the radioactive dose recovered in faeces and 18% in urine, with most of the elimination ( &gt; 85%) occurring within 96 hours.
Nakon jednokratne peroralne primjene radioaktivno obilježenog (14C) lijeka Sivextro natašte, veći dio se eliminirao putem jetre, s 81,5% radioaktivne doze pronađene u stolici i 18% u urinu, a veći dio eliminacije ( &gt; 85%) odvio se unutar 96 sati.
Following the administration of multiple doses, daptomycin AUC0-tau were 387, 438, 439 and 466 µg×hr/ml for 12-17 years, 7-11 years, 2-6 years and 1- &lt; 2 years, respectively, indicating that the daptomycin exposure was similar across the different age groups after dose adjustment based on body weight and age.
Nakon primjene višestrukih doza, AUC0-tau daptomicina bila je 387 µg×sat/ml u skupini 12-17 godina, 438 µg×sat/ml u skupini 7-11 godina, 439 µg×sat/ml u skupini 2-6 godina i 466 µg×sat/ml u skupini 1- &lt; 2 godina, što ukazuje na sličnu izloženost daptomicinu unutar različitih dobnih skupina nakon što je doza prilagođena tjelesnoj težini i dobi.
Following the application of ingenol mebutate, most patients ( &gt; 95%) experienced one or more local skin response(s).
Nakon nanošenja ingenol mebutata većina bolesnika ( &gt; 95%) imala je jednu ili više lokalnih kožnih reakcija.
Following the dose of ProQuad, GMTs for measles, mumps, rubella, and varicella were similar to those following a second dose of Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. administered concomitantly at separate injection sites.
Nakon primjene doze cjepiva ProQuad, geometrijski srednji titar za morbile, parotitis i rubelu bio je sličan titru nakon druge doze živog cjepiva protiv varičele (Oka/Merck) i cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. primijenjenih istodobno na različita injekcijska mjesta.
Following treatment with ledipasvir/sofosbuvir with ribavirin for 12 weeks in patients with decompensated disease (irrespective of liver transplantation status), 3/7 patients with baseline NS5A RAVs conferring &gt; 100-fold reduced susceptibility to ledipasvir relapsed, as compared to 4/68 in those without any baseline RAVs or RAVs conferring ≤ 100-fold reduced susceptibility to ledipasvir.
Nakon liječenja ledipasvirom/sofosbuvirom s ribavirinom provedenog tijekom 12 tjedana u pacijenata s dekompenziranom bolešću (bez obzira na njihov transplantacijski status), 3/7 pacijenata s početnim NS5A RAV-ovima koji nose &gt; 100 puta smanjenu osjetljivost na ledipasvir imalo je relaps, u usporedbi s 4/68 pacijenata bez ikakvih početnih RAV-ova ili RAV-ova koji nose ≤ 100 puta smanjenu osjetljivost na ledipasvir.
Following treatment with ledipasvir/sofosbuvir with ribavirin for 12 weeks in post-liver transplant patients with compensated liver disease (SOLAR-1), none (n = 8) of the patients with baseline NS5A RAVs conferring a ledipasvir fold-change of &gt; 100 relapsed.
Nakon liječenja ledipasvirom/sofosbuvirom s ribavirinom provedenog tijekom 12 tjedana u pacijenata poslije transplantacije jetre s kompenziranom bolešću jetre (SOLAR-1), nijedan (n = 8) od pacijenata s početnim NS5A RAV-ovima koji nose promjenu osjetljivosti na ledipasvir &gt; 100 nije imao relaps.
Fondaparinux 5 mg (body weight &lt; 50 kg), 7.5 mg (body weight  50kg,  100 kg) or 10 mg (body weight &gt; 100 kg) SC once daily was compared to unfractionated heparin IV bolus (5,000 IU) followed by a continuous IV infusion adjusted to maintain 1.5–2.5 times aPTT control value.
Fondaparinuks u dozi od 5 mg (tjelesna težina &lt; 50 kg), 7,5 mg (tjelesna težina 50 kg, 100 kg) ili 10 mg (tjelesna težina &gt; 100 kg) primijenjen s.c. jednom na dan uspoređivao se s nefrakcioniranim heparinom primijenjenim u obliku i.v. bolusa (5000 i.j.) i nastavljenom kontinuiranom i.v. infuzijom prilagođenom tako da se održava vrijednost APTV-a od 1,5 – 2,5 puta kontrolne vrijednosti.
Fondaparinux is contra-indicated in severe renal impairment (creatinine clearance &lt; 30 ml/min) and should be used with caution in patients with moderate renal impairment (creatinine clearance 30-50 ml/min).
Primjena fondaparinuksa je kontraindicirana u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min), a treba je koristiti uz oprez u bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30 - 50 ml/min).
Fondaparinux should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see section 4.3).
Fondaparinuks ne treba primjenjivati u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min) (vidjeti dio 4.3).
Food low in calcium ( &lt; 50 mg calcium) including fruit, lean ham, beef and unfortified (no added calcium, magnesium or iron) fruit juice, unfortified soya milk and unfortified grain did not significantly impact plasma eltrombopag exposure, regardless of calorie and fat content (see sections 4.2 and 4.5).
Hrana s niskim udjelom kalcija ( &lt; 50 mg kalcija), uključujući voće, nemasnu šunku, govedinu i neobogaćeni (bez dodanog kalcija, magnezija ili željeza) voćni sok, neobogaćeno sojino mlijeko i neobogaćene žitarice, nije značajno utjecala na plazmatsku izloženost eltrombopagu, bez obzira na kalorijsku vrijednost i sadržaj masnoća (vidjeti dijelove 4.2 i 4.5).
For 11 patients, cirrhosis status was missing or inconclusive (FibroTest score &gt; 0.48 to
Za 11 bolesnika, status ciroze je nedostajao ili nije bio jasan (rezultat FibroTesta &gt; 0,48 do
For 300 mg, in studies 1 and 3, the mean decrease from baseline in weekly itch severity score was 9.8 and 8.6, the proportion of patients with UAS7≤6 was 61.7% and 55.6%, and the proportion of patients with complete response (UAS7=0) was 48.1% and 42.5%, respectively, (all p &lt; 0.0001, when compared to placebo).
Za 300 mg, u ispitivanjima 1 i 3, srednje smanjenje u odnosu na početnu vrijednost tjednog rezultata za težinu svrbeža bilo je 9,8 odnosno 8,6, udio bolesnika s UAS7≤6 bio je 61,7% odnosno 55,6%, a udio bolesnika s kompletnim odgovorom (UAS7=0) bio je 48,1% odnosno 42,5%, (za sve p &lt; 0,0001, u usporedbi s placebom).
For administration of a 0.25 ml dose in children aged 2 months to &lt; 3 years, follow the steps below:
Za primjenu doze od 0,25 ml u djece u dobi od 2 mjeseca do &lt; 3 godine slijedite dolje navedene korake:
For adults, dose reduction is recommended if the neutrophil count is &lt; 750/mm3.
U odraslih se preporučuje smanjenje doze ako je broj neutrofila &lt; 750/mm3.
For all of the three monthly assessments completed by the subjects, there was a significant difference between Fortacin and placebo (p &lt; 0.0001).
Statistički značajna razlika između skupina liječenih lijekom Fortacin i placebom javljala se kod sva tri mjesečna ispitivanja (p &lt; 0,0001).
For avibactam the PK-PD index is the percent time of the free drug concentration above a threshold concentration over the dose interval (% fT &gt; CT).
Za avibaktam je indeks farmakokinetičkog/farmakodinamičkog odnosa postotak vremena tijekom intervala doziranja u kojem je koncentracija nevezanog lijeka iznad granične koncentracije (%fT &gt; CT).
For children &gt; 12 months of age, the risk of pain at the injection site may increase with increasing age.
U djece starije od 12 mjeseci, s povećanjem dobi se može povećati rizik od bolnosti na mjestu primjene cjepiva.
For CLL patients whose lymphocyte counts are &gt; 25 x 109/L it is recommended to administer prednisone/prednisolone 100 mg intravenous shortly before administration with MabThera to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome.
U bolesnika s KLL-om koji imaju broj limfocita &gt; 25 x 109/l preporučuje se primjena prednizona/prednizolona u dozi od 100 mg intravenski neposredno prije primjene lijeka MabThera kako bi se smanjila stopa i težina akutne infuzijske reakcije i/ili sindroma otpuštanja citokina.
For CLL patients whose lymphocyte counts are &gt; 25 x 109/L it is recommended to administer prednisone/prednisolone 100 mg intravenous shortly before infusion with MabThera to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome.
U bolesnika s KLL-om koji imaju broj limfocita &gt; 25 x 109/l preporučuje se primjena prednizona/prednizolona u dozi od 100 mg intravenski neposredno prije infuzije lijeka MabThera kako bi se smanjila stopa i težina akutne infuzijske reakcije i/ili sindroma otpuštanja citokina.
For DELTOID injection, if the patient weighs &lt; 90 kg, use the 1-inch, 23 gauge needle (25.4 mm x 0.64 mm) (needle with blue colored hub); if the patient weighs ≥ 90 kg, use the 1½-inch, 22 gauge needle (38.1 mm x 0.72 mm) (needle with grey coloured hub).
Za injekciju u DELTOIDNI mišić, ako je bolesnikova tjelesna težina &lt; 90 kg, uzmite iglu dimenzija 25,4 mm x 0,64 mm (1 inč, veličina 23 G) (iglu s plavim čepom); a ako je bolesnikova tjelesna težina  90 kg, uzmite iglu dimenzija 38,1 mm x 0,72 mm (1½ inča, veličina 22 G) (iglu sa sivim čepom).
for dogs &gt; 40 kg
za pse &gt; 40 kg
for dogs &gt; 10–20 kg
za pse &gt; 10-20 kg
for dogs &gt; 2.5–5 kg
za pse &gt; 2,5-5 kg
for dogs &gt; 20–40 kg
za pse &gt; 20-40 kg
for dogs &gt; 40–60 kg
za pse &gt; 40-60 kg
for dogs &gt; 5–10 kg
za pse &gt; 5-10 kg
For doses &lt; 90 mg, dilute Caelyx in 250 ml, and for doses  90 mg, dilute Caelyx in 500 ml.
Za doze &lt; 90 mg, razrijedite Caelyx u 250 ml, a za doze  90 mg, razrijedite Caelyx u 500 ml.
For doses &lt; 90 mg: dilute Caelyx in 250 ml 5% (50 mg/ml) glucose solution for infusion.
Za doze &lt; 90 mg: Caelyx razrijediti u 250 ml 5%-tne (50 mg/ml) otopine glukoze za infuziju.
For doses of 20 mg vortioxetine once daily, the incidences of nausea and constipation were higher in patients aged ≥65 years (42% and 15%, respectively) than in patients aged &lt; 65 years (27% and 4%, respectively)(see section 4.4).
Incidencija mučnine i konstipacije kod doza od 20 mg vortioksetina jednom dnevno je bila viša kod bolesnika u dobi ≥ 65 godina (42% odnosno 15%) nego kod bolesnika u dobi &lt; 65 godina (27% odnosno 4%) (vidjeti dio 4.4).
For E. coli, Campylobacter and Enterococci, both wild type and non-wild type phenotypes were observed (MIC range 1– &gt; 64 µg/ml).
Za E. coli, Camplylobacter i enterokoke, oba tipa, i divlji i ne divlji fenotipovi su zabilježena (MIC raspon 1- &gt; 64 µg/ml).
For E. coli, Campylobacter and Enterococci, both wild type and non-wild type phenotypes were observed (MIC range 1– &gt; 64 µg/ml).
Za E. coli, Camplylobacter i enterokoka, oba tipa i divljeg i ne divljeg fenotipa su zabilježena. (MIC raspon 1- &gt; 64 µg/ml).
For each of the seven common serotypes, &gt; 96% and &gt; 90% of the Prevenar 13 recipients reached an OPA titre ≥ 1:8 one month after the primary series in studies 006 and 004, respectively.
Na svaki od 7 čestih serotipova, &gt; 96 % ispitanika u ispitivanju 006 i &gt; 90 % ispitanika u ispitivanju 004 koji su primili Prevenar 13 postiglo je OPA titar od ≥ 1:8 mjesec dana nakon serije primarnog cijepljenja.
For each of the seven common serotypes, &gt; 96% and &gt; 90 % of the Prevenar 13 recipients reached an OPA titre ≥ 1:8 one month after the primary series in studies 006 and 004, respectively.
Na svaki od 7 čestih serotipova, &gt; 96 % ispitanika u ispitivanju 006 i &gt; 90 % ispitanika u ispitivanju 004 koji su primili Prevenar 13 postiglo je OPA titar od ≥ 1:8 mjesec dana nakon serije primarnog cijepljenja.
For each subsequent drop &lt; 0.5 x 109/l
Kod svakog sljedećeg pada na
For each subsequent drop &lt; 25 x 109/l
Kod svakog sljedećeg pada na
For each subsequent drop below &lt; 0.5 x 109/L Interrupt lenalidomide treatment
Kada broj neutrofila Preporučeni tijek liječenja svaki sljedeći put padne ispod 0,5 x 109/L privremeno prekinuti liječenje
For each subsequent drop below &lt; 0.5 x 109/L Interrupt lenalidomide treatment
svaki sljedeći put padne ispod 0,5 x 109/L privremeno prekinuti liječenje
For each subsequent drop below &lt; 0.5 x 109/L Interrupt lenalidomide treatment
svaki sljedeći put padne ispod 0,5 x 109/L privremeno prekinuti liječenje lenalidomidom vrati se na ≥ 0,5 x 109/L nastaviti s lenalidomidom pri sljedećoj nižoj
For ENABLE 1, 682 patients were randomised to the antiviral treatment phase; however 2 subjects then withdrew consent prior to receiving antiviral therapy. p-value &lt; 0.05 for eltrombopag versus placebo
U ENABLE 1 ispitivanju, 682 bolesnika su randomizirana za fazu antivirusnog liječenja; međutim, 2 su ispitanika povukla pristanak prije početka uzimanja antivirusnog liječenja. p-vrijednost &lt; 0,05 za eltrombopag u odnosu na placebo
For further information about the alli weight loss programme visit &lt; www.xxx.xxx &gt; .
Za daljnje informacije o alli programu za smanjenje tjelesne težine posjetite &lt; www.xxx.xxx &gt; .
For HBeAg-negative/anti-HBe-positive patients: HBV DNA &lt; 2 x 104 copies/ml
Za HBeAg-negativne / anti-HBe-pozitivne bolesnike: HBV DNK &lt; 2 x 104 kopija/ml
For HCV/HIV co-infected patients receiving PegIntron in combination with ribavirin, other undesirable effects (that were not reported in mono-infected patients) which have been reported in the larger studies with a frequency &gt; 5 % were: oral candidiasis (14 %), lipodystrophy acquired (13 %), CD4 lymphocytes decreased (8 %), appetite decreased (8 %), gamma-glutamyltransferase increased (9 %), back pain (5 %), blood amylase increased (6 %), blood lactic acid increased (5 %), cytolytic hepatitis (6 %), lipase increased (6 %) and pain in limb (6 %).
U bolesnika s istodobnom infekcijom HCV-om i HIV-om koji su primali PegIntron u kombinaciji s ribavirinom ostali neželjeni učinci (koji nisu prijavljeni u bolesnika inficiranih samo jednim virusom) prijavljeni u većim kliničkim ispitivanjima s učestalošću od &gt; 5% uključuju: oralnu kandidijazu (14%), stečenu lipodistrofiju (13%), smanjen broj CD4 limfocita (8%), oslabljen tek (8%), povišene vrijednosti gama-glutamiltransferaze (9%), bol u leđima (5%), povišene vrijednosti amilaze u krvi (6%), povišene vrijednosti mliječne kiseline u krvi (5%), citolitički hepatitis (6%), povišene vrijednosti lipaze (6%) i bol u udovima (6%).
For HCV/HIV co-infected patients receiving ribavirin in combination with peginterferon alfa-2b, other adverse reactions (that were not reported in mono-infected patients) which have been reported in the studies with a frequency &gt; 5 % were: oral candidiasis (14 %), lipodystrophy acquired (13 %), CD4 lymphocytes decreased (8 %), appetite decreased (8 %), gamma-glutamyltransferase increased (9 %), back pain (5 %), blood amylase increased (6 %), blood lactic acid increased (5 %), cytolytic hepatitis (6 %), lipase increased (6 %) and pain in limb (6 %).
U bolesnika s istodobnom infekcijom HCV-om i HIV-om koji primaju ribavirin u kombinaciji s peginterferonom alfa-2b, ostale nuspojave (koje nisu bile prijavljene u bolesnika s monoinfekcijom) prijavljene u ispitivanjima s učestalošću od &gt; 5% uključivale su: oralnu kandidijazu (14%), stečenu lipodistrofiju (13%), smanjen broj CD4 limfocita (8%), smanjen tek (8%), povišene vrijednosti gama- glutamiltransferaze (9%), bol u leđima (5%), povišene vrijednosti amilaze u krvi (6%), povišene vrijednosti mliječne kiseline u krvi (5%), citolitički hepatitis (6%), povišene vrijednosti lipaze (6%) i bol u udovima (6%).
For HCV/HIV co-infected patients receiving ribavirin in combination with peginterferon alfa-2b, other adverse reactions (that were not reported in mono-infected patients) which have been reported in the studies with a frequency &gt; 5 % were: oral candidiasis (14 %), lipodystrophy acquired (13 %), CD4 lymphocytes decreased (8 %), appetite decreased (8 %), gamma-glutamyltransferase increased (9 %), back pain (5 %), blood amylase increased (6 %), blood lactic acid increased (5 %), cytolytic hepatitis (6 %), lipase increased (6 %) and pain in limb (6 %).
U bolesnika s istodobnom infekcijom HCV-om i HIV-om koji primaju ribavirin u kombinaciji s peginterferonom alfa-2b, ostale nuspojave (koje nisu bile prijavljene u bolesnika s monoinfekcijom) prijavljene u ispitivanjima s učestalošću od &gt; 5% uključivale su: oralnu kandidijazu (14%), stečenu lipodistrofiju (13%), smanjen broj CD4 limfocita (8%), smanjen tek (8%), povišene vrijednosti gama-glutamiltransferaze (9%), bol u leđima (5%), povišene vrijednosti amilaze u krvi (6%), povišene vrijednosti mliječne kiseline u krvi (5%), citolitički hepatitis (6%), povišene vrijednosti lipaze (6%) i bol u udovima (6%).
For HCV/HIV co-infected patients receiving ribavirin in combination with peginterferon alfa-2b, other adverse reactions (that were not reported in mono-infected patients) which have been reported in the studies with a frequency &gt; 5% were: oral candidiasis (14%), lipodystrophy acquired (13%), CD4 lymphocytes decreased (8%), appetite decreased (8%), gamma-glutamyltransferase increased (9%), back pain (5%), blood amylase increased (6%), blood lactic acid increased (5%), cytolytic hepatitis (6%), lipase increased (6%) and pain in limb (6%).
U bolesnika s istodobnom infekcijom HCV-om i HIV-om koji primaju ribavirin u kombinaciji s peginterferonom alfa-2b, ostale nuspojave (koje nisu bile prijavljene u bolesnika s monoinfekcijom) prijavljene u ispitivanjima s učestalošću &gt; 5 % uključivale su: oralnu kandidijazu (14 %), stečenu lipodistrofiju (13 %), smanjen broj CD4 limfocita (8 %), smanjen tek (8 %), povišenje gama- glutamiltransferaze (9 %), bol u leđima (5 %), povišenje amilaze u krvi (6 %), povišenje mliječne kiseline u krvi (5 %), citolitički hepatitis (6 %), povišenje lipaze (6 %) i bol u udovima (6 %).
For HCV/HIV co-infected patients receiving ViraferonPeg in combination with ribavirin, other undesirable effects (that were not reported in mono-infected patients) which have been reported in the larger studies with a frequency &gt; 5 % were: oral candidiasis (14 %), lipodystrophy acquired (13 %), CD4 lymphocytes decreased (8 %), appetite decreased (8 %), gamma-glutamyltransferase increased (9 %), back pain (5 %), blood amylase increased (6 %), blood lactic acid increased (5 %), cytolytic hepatitis (6 %), lipase increased (6 %) and pain in limb (6 %).
U bolesnika s istodobnom infekcijom HCV-om i HIV-om koji su primali ViraferonPeg u kombinaciji s ribavirinom ostali neželjeni učinci (koji nisu prijavljeni u bolesnika inficiranih samo jednim virusom) prijavljeni u većim kliničkim ispitivanjima s učestalošću od &gt; 5% uključuju: oralnu kandidijazu (14%), stečenu lipodistrofiju (13%), smanjen broj CD4 limfocita (8%), oslabljen tek (8%), povišene vrijednosti gama-glutamiltransferaze (9%), bol u leđima (5%), povišene vrijednosti amilaze u krvi (6%), povišene vrijednosti mliječne kiseline u krvi (5%), citolitički hepatitis (6%), povišene vrijednosti lipaze (6%) i bol u udovima (6%).
For instructions on dilution of the medicinal product before administration, see section 6.6. sJIA and pJIA Patients &lt; 30 kg
Za upute o razrijeđivanju lijeka prije primjene, vidjeti dio 6.6. Bolesnici sa sJIA i pJIA tjelesne težine &lt; 30 kg
For instructions on reconstitution &amp; dilution of the medicinal product before administration, see section 6.6.
Za upute o pripremi i razrjeđivanju lijeka prije primjene, vidjeti dio 6.6.
For large cats &gt; 5 kg – 8 kg
Za velike mačke &gt; 5 kg -8 kg
For large cats &gt; 5 kg – 8 kg
Za velike mačke &gt; 5 kg-8 kg
for large cats &gt; 6.25 – 12.5 kg
za velike mačke &gt; 6,25 - 12,5 kg
for large dogs ( &gt; 20 –40 kg)
za velike pse ( &gt; 20-40 kg)
for large dogs ( &gt; 20–40 kg)
za velike pse ( &gt; 20-40 kg)
for large dogs &gt; 20 – 40 kg
za velike pse &gt; 20 - 40 kg
For medium cats &gt; 2.5 kg – 5 kg
Za srednje velike mačke ≥ 2,5 kg - 5 kg
For medium cats &gt; 2.5 kg – 5 kg
Za srednje velike mačke ≥ 2,5 kg-5 kg
for medium-sized cats &gt; 2.8 – 6.25 kg
za srednje velike mačke &gt; 2,8 - 6,25 kg
for medium-sized dogs ( &gt; 10 –20 kg)
za pse srednje velike pse ( &gt; 10-20 kg)
for medium-sized dogs ( &gt; 10–20 kg)
za srednje velike pse ( &gt; 10-20 kg)
for medium-sized dogs &gt; 10 – 20 kg
za srednje velike pse &gt; 10 - 20 kg